Browse drugs

…r infant per full course under the baseline scenario.Conclusion Pro/synbiotic administration in early life may be feasible and bear similar c…

…aluations and were followed for the development of RA. Synovial FAPI uptake was quantified and related to demographic characteristic…

…nal risk (HR = 1.50, p=0.004).Discussion These findings suggest cannabis use is linked to elevated risk of motor worsening in MS, this e…

…results through Week 48, during which all participants received Fenebrutinib 200 mg BID.Results 99 participants enrolled in the OLE; and 96 …

…y-six percent were on DMT at the time of relapse, most commonly glatiramer acetate. Average gestational age at birth was 39.3 weeks and 55% of par…

…alth outcomes, indicating that breastfeeding is compatible with ocrelizumab.ruth.dobson@qmul.ac.uk…

…l-tolerated, with no serious adverse events reported.Conclusion Nipocalimab demonstrated both efficacy and safety in a 6-month trial involv…

…es in WASO in Q2-4 of the night were numerically larger in both daridorexant dose groups versus placebo.. At M1 and M3, both daridorexant 50…

…ABI), patients are often commenced on anti-seizure medications (ASM). There are risks associated with indefinite ASM use but no evi…

…althy adults aged 18–50 years will be randomised 1:1 to receive PCV15 or placebo. Participants will be considered enrolled on the tri…

…cantly by treatment group (0.025 (95% CI 0.013 to 0.037) in the azithromycin group and 0.022 (95% CI 0.011 to 0.033) in placebo (p=0.688)). …

…stoperative outcomes. This trial aims to compare the effects of propofol, etomidate and remimazolam on the incidence of PIH in older adu…